Actavis and Pfizer settle Celebrex litigation

Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pfizer expects $1.9bn loss due to patent expirations

31 July 2018 US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.

Big Pharma

Pfizer drops Xeljanz patent suits

20 April 2021 Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.

Americas

Pfizer’s Wyeth sues Novartis’ Sandoz over breast cancer drug patent

16 November 2021 Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx.

More on this story

Americas

Pfizer expects $1.9bn loss due to patent expirations

31 July 2018 US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.

Big Pharma

Pfizer drops Xeljanz patent suits

20 April 2021 Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.

Americas

Pfizer’s Wyeth sues Novartis’ Sandoz over breast cancer drug patent

16 November 2021 Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx.

More on this story

Americas

Pfizer expects $1.9bn loss due to patent expirations

31 July 2018 US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.

Big Pharma

Pfizer drops Xeljanz patent suits

20 April 2021 Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.

Americas

Pfizer’s Wyeth sues Novartis’ Sandoz over breast cancer drug patent

16 November 2021 Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers

Actavis and Pfizer settle Celebrex litigation

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features